A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer

ClinicalTrials.gov ID: NCT00663832

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00663832. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Single Arm, Phase Ib Dose Finding Study of i.v. Panobinostat (LBH589) With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase Ib dose escalation study is designed to characterize the safety, tolerability and preliminary efficacy of i.v. panobinostat (LBH589) in combination with docetaxel and prednisone in the 1st line treatment of patients with hormone refractory prostate cancer.

Study identification

NCT ID: NCT00663832
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Novartis Pharmaceuticals; Industry
Enrollment: 44 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

LBH589 (i.v. panobinostat) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2008 (Type not available)
Primary completion: Dec 2011 (Actual)
Completion: Not listed
Last update posted: Dec 19, 2020

Started 2008

United States locations

U.S. sites: 7
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Novartis Investigative Site	Rockville	Maryland	20850	—
Novartis Investigative Site	Detroit	Michigan	48201	—
Novartis Investigative Site	St Louis	Missouri	63110	—
Novartis Investigative Site	Las Vegas	Nevada	89135	—
Novartis Investigative Site	New York	New York	10021	—
Novartis Investigative Site	Durham	North Carolina	27710	—
Novartis Investigative Site	Portland	Oregon	97239	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00663832, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 19, 2020 · Synced Nov 15, 2026